Tesaglitazar AstraZeneca

IDrugs

Volumn 5, Issue 9, 2002, Pages 924-926

  Davis, Tim ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; AR H 39242; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; SB 219994; TESAGLITAZAR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC OBESITY; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0141731334     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. 275466 Astra R&D presentation, London, UK. Muhsin M IDDB Meeting Report 1998 January 23
2. 370612 Role of peroxisome proliferator-activated receptors in atherosclerosis. Winegar DA, Su JL, Kliewer SA Curr Opin Cardiovasc Pulm Renal Invest Drugs 2000 2 3 233-243
3. 377656 AstraZeneca R&D pipeline: NCEs. AstraZeneca plc Company World Wide Web Site 2000 August 01
4. 412643 AZ-242, a novel PPARα/γ agonist, has potent and efficient insulin-sensitizing and antidyslipidemic properties in ob/ob mice and fa/fa Zucker rats. Kjellstedt A, Oakes N, Svensson L, Carlsson AC, Ljung B Diabetes 50 Suppl 6 Abs 483-P
5. 412645 AZ-242, a novel di-hydro cinnamate derivative, shows PPARα and PPARγ effects in a double transgenic human apoB/CETP mice mouse model of diet-induced insulin resistance and dyslipidemia. Wallin B, Amrot-Fors L, Bamberg K, Svensson L, Ljung B, Camejo G Diabetes 2001 50 Suppl 6 Abs 484-P
6. 412648 AZ-242, a novel PPARα/γ agonist, improves sensitivity and increases fatty acid uptake into white adipose tissue of high-fat-fed rats. Hegarty BD, Cooney GJ, Oakes ND, Kraegen E, Furler SM Diabetes 2001 50 Suppl 6 Abs 485-P
7. 412649 AZ-242, a novel di-hydro cinnamate derivative, co-crystallized with PPARα and PPARγ. Bamberg K, Cronet P, Petersen J Karlsson U, Folmer R, Boije M Lindstedt EL Diabetes 2001 50 Suppl 6 Abs 487-P
8. 412715 AZ-242, a novel di-hydro cinnamate derivatives, shows PPARα- and PPARγ-mediated effects in vitro and in vivo. Dahhl B, Stling J, Wettesten M, Iarsson L, Alexandersson M, Lindstedt E-L, Karlsson U, Bamberg U Diabetes 2001 50 Suppl 6 Abs 488-P
9. 412726 AZ-242, a novel PPARα/γ agonist, ameliorates glucose and lipid intolerance in obese zucker rats following oral combined glucose and lipid load. Thalen P, Jacinto S, Hulstrand T, Amrotfors L, Camejo G, Wallin B, Svensson L, Brockenhuus H, Ljung B, Oakes N Diabetes 2001 50 Suppl 6 Abs 489-P
10. 413551 American Diabetes Association's - 61st Scientific Sessions (Part IV) - Overnight Report, Philadelphia, PA, USA. Patteson C IDDB Meeting Report 2001 June 22-26
11. 414609 Tissue-specific effects of AZ-242, a novel PPARα/γ agonist, on glucose and fatty acid metabolism in obese Zucker rats: An in vivo simultaneous multi-tracer assessment. Oakes N, Kjellstedt A, Thalen P, Wettesten M, Lofgren L, Ljung B Diabetes 2001 60 Suppl 6 Abs 486-P
12. 442540 Structure of the PPARα and -γ ligand binding domain in complex with AZ-242; Ligand selectivity and agonist activation in the PPAR family. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, Lindstedt EL, Bamberg K Structure 2001 9 8 699-706
13. 454227 AZ-242, a novel PPARα/γ agonist, enhances the severely impaired metabolic flexibility and insulin action in skeletal muscle of obese Zucker rats. Oakes N, Kjellstedt A, Thal P, Ljung B Diabetes 2002 51 2 Abs 446-P
14. 454333 AZ-242, a novel PPARα/γ agonist, improves the HDL-mediated efflux of cholesterol from differentiated, triglyceride-overloaded THP-1 monocytes. Rosengren B, Carina H, Eva HC, Germn C Diabetes 2002 51 2 Abs 579-P
15. 459440 AstraZeneca R&D pipeline: NCEs - 25 July 2002. AztraZeneca plc Company World Wide Web Site 2002 July 25